Navigation Links
Jeffrey Wasserstein Joins Greenhill as Managing Director Focused on the Pharmaceutical Sector
Date:9/10/2012

NEW YORK, Sept. 10, 2012 /PRNewswire/ -- Greenhill & Co., Inc. (NYSE: GHL), a leading independent investment bank, announced today that Jeffrey Wasserstein has joined the Firm in New York to enhance its focus on the pharmaceutical sector.

Mr. Wasserstein has a 20 year history in the pharmaceutical industry in corporate development and commercial operating roles for a series of pharmaceutical companies.  Most recently he served as Senior Vice President of Business Development & Strategy at Fougera Pharmaceuticals, which was recently sold to the Sandoz division of Novartis AG.  Prior to his time at Fougera he spent five years at Dr. Reddy's Laboratories, a leading global generic pharmaceutical company, as founder and President of a branded specialty pharmaceutical subsidiary focused on dermatology as well as the Executive Vice President of North America and a member of Dr. Reddy's Global Management Council.  He began his career in the sector at Schering-Plough Corporation, where he started in a legal role and rose to first head of Corporate Business Development, then President of Schering Canada and later Senior Vice President of the parent company.  Prior to his time at Schering-Plough, he was an attorney at Wachtell, Lipton, Rosen & Katz for six years, focused on mergers and acquisitions advice.

Scott L. Bok, Chief Executive Officer of Greenhill, said, "The health care sector has become a very important part of our business, as an increasing number of companies in health care services, health care devices and pharmaceuticals have opted for our unconflicted, client-focused approach to advising clients on important transactions.  With the addition of Jeff we are significantly increasing our knowledge of the trends and opportunities in the pharmaceutical sector, as well as our access to a much larger range of companies in that sector."

Jeffrey Wasserstein said, "I am very pleased to be joining Greenhill, where I have known some of its partners for many years.  In my new role I can build upon my many relationships in the industry as well as my significant experience as a corporate development and operating executive and as an external advisor.  I look forward to utilizing my deep industry knowledge, an insider's appreciation for the many challenges facing the senior management and boards of companies in the pharmaceutical sector and my significant transaction experience to advise pharmaceutical companies on important transactions and other matters."

Greenhill & Co., Inc. is a leading independent investment bank focused on providing financial advice on significant mergers, acquisitions, restructurings, financings and capital raising to corporations, partnerships, institutions and governments.  It acts for clients located throughout the world from its offices in New York, London, Frankfurt, Stockholm, Sydney, Tokyo, Toronto, Chicago, Dallas, Houston, Los Angeles, Melbourne and San Francisco.

Contact:
Christopher T. Grubb
Chief Financial Officer
Greenhill & Co., Inc.
(212) 389-1800


'/>"/>
SOURCE Greenhill & Co., Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AgaMatrix elects Jeffrey B. Kindler to its Board of Directors
2. Financier Jeffrey Epstein And Mount Sinai Hospital Support 3D Mammograms For Breast Cancer
3. Jeffrey Modell Foundation Opens Diagnostic Center for Primary Immunodeficiencies at Midwest Immunology Clinic
4. The Largest Private Funder Of Melanoma Research Receives Vital Support From Activist Jeffrey Epstein
5. Gerald E. Quirk Joins Choate, Hall & Stewart LLP as Co-Chair of Life Sciences Group
6. Dr. Magnus Persson Joins Cerecors Board of Directors
7. Joseph Rogers Joins SRI International as Executive Director of New Health Sciences Section in Biosciences Division
8. Pharmacy Industry Veteran Joins Millennium Pharmacy Systems as SVP Operations
9. Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman
10. Dr. Gerald Yakatan Joins Imprimis Pharmaceuticals Science and Regulatory Advisory Board
11. MinuteClinic Joins with American Heart Association to Help Americans Reduce High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):